CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis.
OBJECTIVE
Cyclin D1 (CCND1) is a key regulatory protein in the G1/S checkpoint of the cell cycle. We hypothesized that the G870A polymorphism of CCND1 is associated with the risk for cervical cancer and performed a meta-analysis of eligible studies to evaluate this relationship.


METHODS
In a case-control study of 300 patients with newly diagnosed cervical cancer and 312 cancer-free controls who were frequency-matched by age, we genotyped the G870A polymorphism of CCND1 by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A meta-analysis was performed using five case-control studies, including our results.


RESULTS
No significant association was observed between the G870A polymorphism of CCND1 and cervical cancer risk. Further, in our meta-analysis, there was no significant risk of cervical cancer that correlated with the G870A polymorphism of CCND1. In the stratified analysis by race, however, individuals who harbored the AA or AA/AG genotypes were at significantly greater risk compared with GG carriers in the Asian population.


CONCLUSIONS
The G870A polymorphism in CCND1 may not contribute to the etiology of cervical cancer in Chinese populations.
Ni
Jing
J
Department of Gynecology and Obstetrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wang
Meilin
M
Wang
Miaomiao
M
Fu
Shilong
S
Zhou
Delan
D
Zhang
Zhengdong
Z
Han
Suping
S
D000328:Adult; D016022:Case-Control Studies; D019938:Cyclin D1 / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D002583:Uterine Cervical Neoplasms / Q000235:genetics*
C530104:CCND1 protein, human; D019938:Cyclin D1
Nat Rev Cancer. 2006 Oct;6(10):753-63
16990853
Carcinogenesis. 2005 Aug;26(8):1457-64
15845652
Trends Biochem Sci. 1995 May;20(5):187-90
7610482
N Engl J Med. 1998 Feb 12;338(7):423-8
9459645
Breast Cancer Res Treat. 2009 Aug;116(3):571-5
18819000
Gynecol Oncol. 2005 May;97(2):431-5
15863141
Int J Gynecol Cancer. 1999 Jul;9(4):342-347
11240791
Biomarkers. 2009 Jun;14(4):219-25
19489683
Oncogene. 1995 Sep 7;11(5):1005-11
7675441
Lancet Oncol. 2005 Mar;6(3):139-41
15737830
J Biol Chem. 2003 Aug 8;278(32):30339-47
12746453
Clin Sci (Lond). 2006 May;110(5):525-41
16597322
Oncogene. 1998 Apr 2;16(13):1701-12
9582018
Cancer Lett. 2005 Jun 8;223(2):259-63
15896460
Lancet. 2001 Jun 9;357(9271):1831-6
11410191
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Cancer Genet Cytogenet. 2005 Jul 1;160(1):49-54
15949570
Nat Rev Cancer. 2002 May;2(5):342-50
12044010
JAMA. 2001 Dec 26;286(24):3106-14
11754676
Mol Cell Biochem. 2008 Aug;315(1-2):151-7
18548202
Science. 1996 Dec 6;274(5293):1672-7
8939849
Biochem Biophys Res Commun. 2008 May 23;370(1):118-22
18355450